Abstract

Genzyme, though unique, could be a bellwether for US biotech

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Utility patenting of US biotech inventions in non-US countries
Erich E Veitenheimer ... Yi Wang
Industrial Biotechnology | VOL. 7
Erich E Veitenheimer, et. al.Erich E Veitenheimer ... Yi Wang
01 Jun 2011
Correction: 'Genzyme, though unique, could be a bellweather for US biotech'
-
Nature Medicine | VOL. 17
--
01 Mar 2011
The European biotech sector: Could it achieve more?
Sam Fazeli
Journal of Commercial Biotechnology | VOL. 12
Sam FazeliSam Fazeli
01 Oct 2005
The European biotech sector: Could it achieve more?
Sam Fazeli
Journal of Commercial Biotechnology | VOL. 12
Sam FazeliSam Fazeli
01 Oct 2005
View more papers

More From: Nature Medicine

Paper Title
Journal
Date
Author
Generating clinical evidence for treatment and prevention options for long COVID.
Stephanie Buchholz ... Marco Cavaleri
Nature medicine | VOL. -
Stephanie Buchholz, et. al.Stephanie Buchholz ... Marco Cavaleri
28 May 2024
Noninvasive assessment of organ-specific and shared pathways in multi-organ fibrosis using T1 mapping.
Victor Nauffal ... Patrick T Ellinor
Nature medicine | VOL. -
Victor Nauffal, et. al.Victor Nauffal ... Patrick T Ellinor
28 May 2024
How medical schools can prepare students for new technologies.
Chantal Mathieu
Nature medicine | VOL. -
Chantal MathieuChantal Mathieu
27 May 2024
IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Glenn M Chertow ... Myles Wolf
Nature medicine | VOL. -
Glenn M Chertow, et. al.Glenn M Chertow ... Myles Wolf
25 May 2024
View more papers